Ritesh Indulkar / April 10, 2026 / Pharmaceuticals
DSCSA 2025 Compliance Checklist: Is Your Pharma Packaging Line Ready for FDA Enforcement?
- DSCSA urgency: FDA enforcement is active, and US pharmaceutical manufacturers need audit-ready serialization and traceability systems.
- Line-level readiness: Saleable units need compliant 2D Data Matrix barcodes, readable-code inspection, validation, and rejected-code removal.
- Aggregation requirement: Serialized units, cases, and pallets must maintain an accurate parent-child hierarchy for traceability.
- Enterprise reporting: L3/L4 systems should manage serial numbers, EPCIS event data, ERP integration, and complete audit trails.
- US support factor: Local service engineers, validated US packaging formats, and trained operators are critical for enforcement readiness.
The Drug Supply Chain Security Act (DSCSA) is no longer a future obligation.
FDA enforcement is active, deadlines have passed, and the tolerance window for non-compliant pharmaceutical manufacturers in the United States is closing fast.
If you are a pharmaceutical manufacturer, contract packager, CDMO, or third-party logistics provider operating in the US, this checklist is for you.
Use it to audit your current serialization and aggregation capabilities, identify compliance gaps, and take action before your next FDA inspection or trading partner rejection.
Jekson Vision’s USA team, based in West Berlin, New Jersey, has compiled this checklist from direct implementation experience across pharma packaging lines in the United States and the Americas.
What Is DSCSA and Why Does It Matter Now
The Drug Supply Chain Security Act (DSCSA), enacted under the FDA Safety and Innovation Act, requires all members of the pharmaceutical supply chain, manufacturers, repackagers, wholesale distributors, and dispensers, to serialize, track, and trace prescription drug products at the package level.
Key requirements include:
- Unique product identifier (UPI) on every saleable unit — a 2D Data Matrix barcode containing GTIN, serial number, lot number, and expiration date
- Aggregation of serialized units into cases and pallets with parent-child relationships
- Electronic interoperable exchange of traceability data between trading partners
- Drug Traceability System (DTS) enabling end-to-end unit-level tracing
Non-compliance means trading partners can legally refuse your products.
It means FDA warning letters.
In serious cases, it means product seizure.
The DSCSA 2025 Compliance Checklist
SECTION 1 — Serialization at the Line Level (L1/L2)
- Every saleable unit carries a compliant 2D Data Matrix barcode
- Barcode contains: GTIN (01), Serial Number (21), Lot Number (10), Expiration Date (17)
- Print and inspect system verifies every code at line speed — no readable-code failures
- Rejected or unreadable codes are physically removed before leaving the line
- Serialization machine is validated and audit-ready (GAMP 5 / 21 CFR Part 11)
- Line-level serialization data is captured and stored in an L2 system
SECTION 2 — Aggregation (L2/L3)
- Every serialized unit is aggregated into its shipping case (SSCC assigned)
- Every case is aggregated to pallet level with correct parent-child hierarchy
- Aggregation data is captured automatically — not manually logged
- Your system supports ‘commission’, ‘decommission’, ‘ship’, and ‘receive’ events
- Re-aggregation workflows exist for damaged or returned packaging
SECTION 3 — Data Management & L4 Enterprise Reporting
- All serialization and aggregation events are stored in a central L3/L4 system
- Your L4 system can generate EPCIS-compliant event data for trading partner exchange
- System integrates with your ERP (SAP, Oracle, etc.) without manual data entry
- Serial number management (SNM) prevents duplicate or reused serial numbers
- Full audit trail is maintained — every event timestamped and user-attributed
- You can produce a Transaction History (TH), Transaction Information (TI), and Transaction Statement (TS) on demand
SECTION 4 — FDA & Trading Partner Readiness
- Your system supports electronic Product Identifier (ePI) verification with the FDA’s Drug Traceability System (DTS)
- You can respond to an FDA request for traceability data within 24 hours
- Your wholesale distributor and 3PL partners are DSCSA-compliant and connected
- Your system can execute a targeted product recall using serialization data within hours
- Your compliance documentation is current and accessible for FDA inspection
SECTION 5 — US-Specific Operational Checks
- Your US-based serialization vendor has local service engineers (not remote-only support)
- Your SLA guarantees response time in US business hours
- Your system has been validated on the specific carton/bottle formats used in your US facility
- Your team is trained — not just your IT department, but line operators, QA, and logistics
If you checked fewer than 18 of these 22 items, your operation has material DSCSA compliance gaps.
Jekson Vision’s US team offers a free gap analysis for qualifying manufacturers.
Contact our New Jersey office to schedule.
How Jekson Vision Can Help
Jekson Vision USA Inc., located at 403 Bloomfield Drive, West Berlin, NJ, provides end-to-end DSCSA compliance solutions for pharmaceutical manufacturers across the United States.
Our REETRAK system covers L1 through L5, is GS1-compliant, and has been validated on US packaging lines across multiple states.
We are one of the only pharma serialization vendors with:
- A physical US office and warehouse in New Jersey
- Local service engineers covering the NJ–PA–NY–NC pharma corridor
- 21 CFR Part 11-validated software with full audit trail
- Implementation timelines are measured in weeks, not months
Download the printable DSCSA Compliance Checklist PDF, or contact our New Jersey team directly to book a free compliance audit. maketing@jeksonvision.com